Brain Advance Access originally published online on July 22, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 126, No. 10, 2191-2202,
October 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg224
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
1 Department of Neuroinflammation, Institute of Neurology, University College London, London, UK, 2 Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Universite libre de Bruxelles, Brussels, Belgium and 3 Neurorehabilitation Group, Institute of Neurology, University College London, Queen Square, London, UK *These authors contributed equally to this work
Correspondence to: Dr David Baker, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ, UK E-mail: d.baker{at}ion.ucl.ac.uk
Multiple sclerosis is increasingly being recognized as a neurodegenerative disease that is triggered by inflammatory attack of the CNS. As yet there is no satisfactory treatment. Using experimental allergic encephalo myelitis (EAE), an animal model of multiple sclerosis, we demonstrate that the cannabinoid system is neuroprotective during EAE. Mice deficient in the cannabinoid receptor CB1 tolerate inflammatory and excito toxic insults poorly and develop substantial neurodegeneration following immune attack in EAE. In addition, exogenous CB1 agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease in an experimental allergic uveitis model. Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S Al-Izki, G Pryce, G Giovannoni, and D Baker Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography Multiple Sclerosis, July 1, 2009; 15(7): 795 - 801. [Abstract] [PDF]
|
|
|
|
 |
|
 I. J. Lever, M. Robinson, M. Cibelli, C. Paule, P. Santha, L. Yee, S. P. Hunt, B. F. Cravatt, M. R. Elphick, I. Nagy, et al. Localization of the Endocannabinoid-Degrading Enzyme Fatty Acid Amide Hydrolase in Rat Dorsal Root Ganglion Cells and Its Regulation after Peripheral Nerve Injury J. Neurosci., March 25, 2009; 29(12): 3766 - 3780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-s. Jiang, J. Pu, Z.-h. Han, L.-h. Hu, and B. He Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages Cardiovasc Res, March 1, 2009; 81(4): 805 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, D. Feng, G. Liu, Q. Luo, Y. Xu, S. Lin, J. Fei, and L. Xu {gamma}-Aminobutyric Acid Transporter 1 Negatively Regulates T Cell-Mediated Immune Responses and Ameliorates Autoimmune Inflammation in the CNS J. Immunol., December 15, 2008; 181(12): 8226 - 8236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Di Filippo, L A Pini, G P Pelliccioli, P Calabresi, and P Sarchielli Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1224 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Idris, A. Sophocleous, E. Landao-Bassonga, R. J. van't Hof, and S. H. Ralston Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor Endocrinology, November 1, 2008; 149(11): 5619 - 5626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Woolmore, M. Stone, S. Holley, P. Jenkinson, A. Ike, P. Jones, A. Fryer, R. Strange, R. Stephens, D. Langdon, et al. Polymorphisms of the cannabinoid 1 receptor gene and cognitive impairment in multiple sclerosis Multiple Sclerosis, March 1, 2008; 14(2): 177 - 182. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. De Chiara, L. Battistini, G. Bernardi, S. Bernardini, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis Brain, October 1, 2007; 130(10): 2543 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nucci, V. Gasperi, R. Tartaglione, A. Cerulli, A. Terrinoni, M. Bari, C. De Simone, A. F. Agro, L. A. Morrone, M. T. Corasaniti, et al. Involvement of the Endocannabinoid System in Retinal Damage after High Intraocular Pressure-Induced Ischemia in Rats Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 2997 - 3004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. W. Yong, F. Giuliani, M. Xue, A. Bar-Or, and L. M. Metz Experimental models of neuroprotection relevant to multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S32 - S37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, L. Wang, J. Harvey-White, D. Osei-Hyiaman, R. Razdan, Q. Gong, A. C. Chan, Z. Zhou, B. X. Huang, H.-Y. Kim, et al. A biosynthetic pathway for anandamide PNAS, September 5, 2006; 103(36): 13345 - 13350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Bilsland, J. R. T. Dick, G. Pryce, S. Petrosino, V. Di Marzo, D. Baker, and L. Greensmith Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice FASEB J, May 1, 2006; 20(7): 1003 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Shohami and R. Mechoulam Multiple sclerosis may disrupt endocannabinoid brain protection mechanism PNAS, April 18, 2006; 103(16): 6087 - 6088. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Kim, S. J. Won, X. O. Mao, K. Jin, and D. A. Greenberg Molecular Mechanisms of Cannabinoid Protection from Neuronal Excitotoxicity Mol. Pharmacol., March 1, 2006; 69(3): 691 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J P Zajicek, H P Sanders, D E Wright, P J Vickery, W M Ingram, S M Reilly, A J Nunn, L J Teare, P J Fox, and A J Thompson Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1664 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. East, D. Baker, G. Pryce, H. R. Lijnen, M. L. Cuzner, and D. Gveric A Role for the Plasminogen Activator System in Inflammation and Neurodegeneration in the Central Nervous System during Experimental Allergic Encephalomyelitis Am. J. Pathol., August 1, 2005; 167(2): 545 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 CB1 Knockout Mice Sci. Aging Knowl. Environ., June 15, 2005; 2005(24): tg4 - tg4. [Full Text]
|
|
|
|
|
|
B W van Oosten, J Killestein, E M. Mathus-Vliegen, and C H Polman Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist Multiple Sclerosis, June 1, 2004; 10(3): 330 - 332. [Abstract] [PDF]
|
|
|
|
 |
|
 Cannabinoids May Have a Neuroprotective Effect in MS Journal Watch Neurology, February 13, 2004; 2004(213): 7 - 7. [Full Text]
|
|